Today: 1 May 2026

Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking

Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking

Abivax shares fell 9.49% to 99.20 euros in Paris on Thursday, reversing a 6% gain from the previous day. Volume reached about 246,000 shares amid anticipation of Phase 3 trial results for obefazimod in late Q2 2026. A U.S. Form 144 filing showed Sofinnova Crossover I SLP intends to sell up to 1,000,000 ADS. BTIG raised its price target on Abivax to $150 and maintained a “Buy” rating.
8 January 2026
·
Exxon Mobil stock (XOM) rises as filing flags Q4 upstream hit from weaker crude; Jan 30 next

Exxon Mobil stock (XOM) rises as filing flags Q4 upstream hit from weaker crude; Jan 30 next

Exxon Mobil shares rose 3.3% to $122.42 by early afternoon Thursday after the company warned that lower crude prices could cut fourth-quarter upstream earnings by $0.8 billion to $1.2 billion from the prior quarter. Exxon said stronger refining margins may add $0.3 billion to $0.7 billion. The company reports results Jan. 30. Traders are watching oil price swings and estimate changes.
8 January 2026
···
Teleflex (TFX) stock dives on CEO exit and revenue forecast cut — what investors watch next

Teleflex (TFX) stock dives on CEO exit and revenue forecast cut — what investors watch next

Teleflex shares fell 11.7% to $111.76 Thursday after the company announced CEO Liam Kelly’s exit and cut its 2025 revenue forecast. Stuart Randle was named interim chief executive, with a $140,000 monthly stipend and $1.5 million in stock. Teleflex cited weak demand for balloon pumps and OEM order delays. The company expects to report full results in late February or early March.
8 January 2026
·
Why Applied Optoelectronics (AAOI) stock is down today as tech pulls back

Why Applied Optoelectronics (AAOI) stock is down today as tech pulls back

Applied Optoelectronics (AAOI.O) dropped 14.9% to $32.40 in Thursday afternoon trading, with 6.2 million shares traded and an intraday low of $31.70. The decline followed a broader selloff in tech stocks, leaving the Nasdaq down 0.5% midday. Optical networking peers Ciena, Lumentum, and Coherent also fell sharply. Investors are watching Friday’s U.S. payrolls report and AAOI’s earnings update in late February.
8 January 2026
··
Silver price stock SLV slides as index rebalance selling kicks in ahead of U.S. jobs report

Silver price stock SLV slides as index rebalance selling kicks in ahead of U.S. jobs report

iShares Silver Trust dropped 3.5% to $68.50 in midday New York trading, tracking a broader selloff in silver assets as spot silver fell 2.5% to $76.19 an ounce. Traders cited commodity index rebalancing and a stronger dollar ahead of Friday’s U.S. payrolls report. Silver miners slipped less, down 0.4% to 1%. Sterling weakened for a third day as the dollar firmed.
8 January 2026
······
Dow Jones ETF DIA rises as tech slips and Trump defense headlines jar Wall Street before payrolls

Dow Jones ETF DIA rises as tech slips and Trump defense headlines jar Wall Street before payrolls

The SPDR Dow Jones Industrial Average ETF Trust rose 0.6% to $492.73 Thursday as the Dow climbed 304 points, while the Nasdaq slipped on tech losses. Weekly jobless claims increased to 208,000 and continuing claims reached 1.914 million. Defense stocks rebounded after President Trump proposed a $1.5 trillion military budget for 2027. Investors await Friday’s U.S. nonfarm payrolls report.
8 January 2026
··
Regencell Bioscience (RGC) stock slides about 18% after five volatility halts on Nasdaq

Regencell Bioscience (RGC) stock slides about 18% after five volatility halts on Nasdaq

Regencell Bioscience shares plunged 18.5% to $43.10 Thursday after hitting $69.97 earlier in the session, triggering five volatility halts. Over 3 million shares traded by early afternoon, far above average. The company has warned of “substantial doubt” about its ability to continue operating and reported net losses of $3.58 million for the year ended June 2025. No company statement explained the sharp swings.
8 January 2026
··
Why Westlake stock is jumping today after its ACI deal filing

Why Westlake stock is jumping today after its ACI deal filing

Westlake Corp shares rose 7.4% to $79.98 Thursday after the company said it completed its acquisition of ACI/Perplastic Group’s global compounding solutions businesses. The deal expands Westlake’s manufacturing into Portugal, Romania, and Tunisia. Financial terms were not disclosed. Other major U.S. chemical stocks also gained.
8 January 2026
·
UnitedHealth Group Incorporated stock rises as House summons insurer CEOs; investors eye two January dates

UnitedHealth Group Incorporated stock rises as House summons insurer CEOs; investors eye two January dates

UnitedHealth shares rose 1.3% to $346.11 after U.S. House lawmakers called major health insurer CEOs to testify on coverage affordability January 22. Senators Wyden and Warren accused UnitedHealth of withholding documents in a nursing-home probe, setting a January 28 deadline. TPG is in advanced talks to buy UnitedHealth’s Optum UK unit for up to £1.4 billion, Sky News reported.
8 January 2026
····
IREN stock jumps nearly 8% as AI data-center trade returns; earnings are the next test

IREN stock jumps nearly 8% as AI data-center trade returns; earnings are the next test

IREN shares jumped 7.7% to $46.99 in Thursday afternoon trading, tracking gains in data-center stocks after Applied Digital announced talks with a major cloud customer. IREN operates U.S. and Canadian data centers for bitcoin mining and AI compute, with about 1,896 Nvidia GPUs. Its $9.7 billion, five-year GPU cloud deal with Microsoft includes strict delivery terms. Next results are expected in February, with focus on GPU rollout and funding.
8 January 2026
····
AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie shares fell 3.7% to $224.84 Thursday after the company denied takeover talks with Revolution Medicines and flagged a $1.3 billion fourth-quarter charge tied to R&D and milestone payments. AbbVie trimmed its 2025 profit forecast, setting adjusted earnings at $9.90 to $9.94 per share. Revolution Medicines dropped 5.5%. Wolfe Research downgraded AbbVie, citing limited upside.
8 January 2026
··
Trump’s New $100 U.S. National Park Fee for Foreign Tourists Kicks In — and 10 States Race Ahead in Crypto

Trump’s New $100 U.S. National Park Fee for Foreign Tourists Kicks In — and 10 States Race Ahead in Crypto

Foreign visitors to 11 major U.S. national parks, including Yosemite and Yellowstone, now pay a $100 per-person surcharge on top of regular entrance fees, the National Park Service said. The Center for Biological Diversity has sued, arguing the fee and new resident/nonresident pass categories violate federal law. The new policy requires staff to check IDs at park gates and changes how tour groups are processed.
8 January 2026
Nebius (NBIS) stock bounces back near $100 as Nvidia Rubin talk keeps AI cloud names jumpy

Nebius (NBIS) stock bounces back near $100 as Nvidia Rubin talk keeps AI cloud names jumpy

Nebius shares rose nearly 4% to $100.03 in midday Nasdaq trading Thursday after the AI cloud company announced plans to offer early access to Nvidia’s Rubin platform starting in the second half of 2026. The stock rebounded after a previous session drop, while Nvidia slipped 2%. Investors are watching a Jan. 29 product webinar and the company’s next earnings update in mid-February.
8 January 2026
····
1 … 755 756 757 758 759 … 1,889

Stock Market Today

  • Community Financial System (CBU) Stock Gains Momentum Amid Mixed Valuation Signals
    May 1, 2026, 5:21 PM EDT. Community Financial System (CBU) has captured investor attention with its recent share price rising 1.82% in one day and 8.03% over the past month. The stock shows a 1-year total return of 18.79% and a 3-year return of 48.42%, signaling sustained momentum. Trading at $63.36, the bank's price-to-earnings (P/E) ratio stands at 15.2x, above the US Banks industry average of 11.4x and a fair estimate of 14x, indicating potential overvaluation. However, the P/E is below a peer group average of 16.3x. Investors must consider risks including regional bank pressures and potential slowdowns in fee-based segments like wealth and insurance. Valuation models diverge, with discounted cash flow estimates suggesting further analysis is needed to confirm true intrinsic value.

Latest article

Why Zscaler Stock Jumped Today Despite a Wall Street Target Cut

Why Zscaler Stock Jumped Today Despite a Wall Street Target Cut

1 May 2026
Zscaler shares climbed 7% to $139.81 Friday despite a price-target cut by Citizens JMP to $210. The move followed a sector rally after Atlassian raised its forecast. Zscaler reported 26% revenue growth last quarter and expanded AI security features in its GovCloud product. Customers remain cautious on large deals, with longer approval times noted.
Xanadu Quantum Technologies Stock Gets First Big Test as Q1 Results Date Lands

Xanadu Quantum Technologies Stock Gets First Big Test as Q1 Results Date Lands

1 May 2026
Xanadu Quantum Technologies will report first-quarter results May 14, its first earnings since going public last month. Shares closed at $36.12 Friday, up $7.05, with 4.28 million traded. The company posted a $70.7 million net loss in 2025 and raised $302 million via a SPAC merger. Investors will watch the call for updates on spending, cash runway, and funding prospects.
Clorox Stock Slumps After Profit Forecast Cut as Purell Deal and Oil Costs Bite

Clorox Stock Slumps After Profit Forecast Cut as Purell Deal and Oil Costs Bite

1 May 2026
Clorox cut its fiscal 2026 profit forecast, citing higher energy costs, inventory timing, and expenses from its Purell acquisition; shares fell 9.6% to $87.11. The company now expects adjusted EPS of $5.45–$5.65, down from $5.95–$6.30, and organic sales to drop about 9%. Third-quarter sales were flat at $1.67 billion, while gross margin fell to 43.2%.
Go toTop